COMMUNIQUÉS West-GlobeNewswire

Codexis to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

26/09/2019 - 13:00

REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor Fitzgerald Global Healthcare [...]

Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

26/09/2019 - 13:00

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]

Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration

26/09/2019 - 13:00

EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has resubmitted its New Drug Application ( [...]

FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy

26/09/2019 - 13:00

SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class hypoxia-inducible factor prolyl [...]

ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019

26/09/2019 - 13:00

YONKERS, N.Y., Sept. 26, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins [...]

OptiNose Announces License Agreement Related to ONZETRA XSAIL

26/09/2019 - 13:00

YARDLEY, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- OptiNose , Inc. (Optinose) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the [...]

EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

26/09/2019 - 13:00

WATERTOWN, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today [...]

Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019

26/09/2019 - 12:35

Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019 Lugano, Switzerland, September 26, 2019 – Helsinn, the Swiss pharmaceutical group focused on building quality cancer [...]

Precision BioSciences to Present at Upcoming Industry and Investor Conferences

26/09/2019 - 12:30

Company to Participate in the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa, Chardan Genetic Medicines Conference and Jefferies Gene Therapy Summit DURHAM, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE [...]

Treos Bio Reports Updated Positive Results from a Phase 1/2 Clinical Trial of Precision Cancer Vaccine Plus Maintenance Therapy in Patients with Metastatic Colorectal Cancer

26/09/2019 - 11:15

The company presents four scientific posters on its proprietary platform technology at the 2019 ESMO Annual Congress LONDON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Treos Bio Limited, which is developing personal cancer [...]

Demant A/S: Estimated financial impact of IT incident reflected in outlook

26/09/2019 - 08:05

Company announcement no 2019- 11 26 September 2019 Estimated financial impact of IT incident reflected in outlook As previously communicated in Company announcements on 3, 4 and 17 September, the Demant Group [...]

Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial

26/09/2019 - 08:00

Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial Herantis Pharma Plc Company release 26 September 2019 at 9:00 AM Herantis Pharma Plc (“Herantis” or “Company”) announced today an update [...]

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2019

26/09/2019 - 07:30

EVENTS IN FIRST QUARTER Oasmia presented results from two clinical studies of Docecal in patients with metastatic breast cancer The Board of Directors appointed a special examiner to give all shareholders basis for [...]

ASIT biotech Firmly on Course for Readout of Phase III Clinical Study in Grass Pollen Allergy

26/09/2019 - 07:00

The Company has passed the Last Patient Last Visit (LPLV) milestone in the pivotal gp-ASIT+™ Phase III trial and remains on track to deliver primary efficacy results in December 2019. ASIT biotech is collaborating with [...]

Monalizumab to advance to Phase III in head and neck cancer

26/09/2019 - 07:00

Marseille, France, September 26, 2019, 7:00 AM CEST Innate Pharma SA (the “Company” or “Innate” - Euronext Paris: FR0010331421 – IPH), today announced that AstraZeneca (LSE/STO/NYSE: AZN) will advance monalizumab into a [...]

Monalizumab va entrer en Phase III dans le cancer de la tête et du cou

26/09/2019 - 07:00

Marseille, 26 septembre 2019, 7h00 Innate Pharma SA (« Innate » ou la « Société » - Euronext Paris : FR0010331421 – IPH) a annoncé aujourd’hui qu’AstraZeneca (LSE/STO/NYSE: AZN) a décidé de tester monalizumab dans un [...]

Acacia Pharma Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020

26/09/2019 - 07:00

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 26 September 2019: Acacia Pharma Group plc (“Acacia [...]

Following Record Q2 Results, Nova Leap Health Corp. Announces Execution of Definitive Agreement to Acquire Home Care Business in Massachusetts

25/09/2019 - 23:23

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN HALIFAX, Nova Scotia, Sept. 25, 2019 (GLOBE NEWSWIRE) -- NOVA [...]

Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense

25/09/2019 - 22:15

GAITHERSBURG, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing [...]